These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36717525)

  • 41. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
    Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
    Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BRCA2 germline mutations in familial pancreatic carcinoma.
    Hahn SA; Greenhalf B; Ellis I; Sina-Frey M; Rieder H; Korte B; Gerdes B; Kress R; Ziegler A; Raeburn JA; Campra D; Grützmann R; Rehder H; Rothmund M; Schmiegel W; Neoptolemos JP; Bartsch DK
    J Natl Cancer Inst; 2003 Feb; 95(3):214-21. PubMed ID: 12569143
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Familial pancreatic carcinoma in Jews.
    Lynch HT; Deters CA; Lynch JF; Brand RE
    Fam Cancer; 2004; 3(3-4):233-40. PubMed ID: 15516847
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Variation in precursor lesions of pancreatic cancer among high-risk groups.
    Potjer TP; Schot I; Langer P; Heverhagen JT; Wasser MN; Slater EP; Klöppel G; Morreau HM; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bargello M; Gress TM; Vasen HF; Bartsch DK; ;
    Clin Cancer Res; 2013 Jan; 19(2):442-9. PubMed ID: 23172884
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium.
    Plaschke J; Engel C; Krüger S; Holinski-Feder E; Pagenstecher C; Mangold E; Moeslein G; Schulmann K; Gebert J; von Knebel Doeberitz M; Rüschoff J; Loeffler M; Schackert HK
    J Clin Oncol; 2004 Nov; 22(22):4486-94. PubMed ID: 15483016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic
    Overbeek KA; Rodríguez-Girondo MD; Wagner A; van der Stoep N; van den Akker PC; Oosterwijk JC; van Os TA; van der Kolk LE; Vasen HFA; Hes FJ; Cahen DL; Bruno MJ; Potjer TP
    J Med Genet; 2021 Apr; 58(4):264-269. PubMed ID: 32482799
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants.
    Murali K; Dwarte TM; Nikfarjam M; Tucker KM; Vaughan RB; Efthymiou M; Collins A; Spigelman AD; Salmon L; Johns AL; Williams DB; Delatycki MB; John T; Stoita A
    Hered Cancer Clin Pract; 2021 Aug; 19(1):33. PubMed ID: 34399810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas.
    Harinck F; Kluijt I; van der Stoep N; Oldenburg RA; Wagner A; Aalfs CM; Sijmons RH; Poley JW; Kuipers EJ; Fockens P; van Os TA; Bruno MJ
    J Med Genet; 2012 Jun; 49(6):362-5. PubMed ID: 22636603
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical characterization and mutation spectrum in Hispanic families with adenomatous polyposis syndromes.
    Cruz-Correa M; Diaz-Algorri Y; Mendez V; Vazquez PJ; Lozada ME; Freyre K; Lathroum L; Gonzalez-Pons M; Hernandez-Marrero J; Giardiello F; Rodriguez-Quilichini S
    Fam Cancer; 2013 Sep; 12(3):555-62. PubMed ID: 23460355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Familial sarcoma: challenging pedigrees.
    Lynch HT; Deters CA; Hogg D; Lynch JF; Kinarsky Y; Gatalica Z
    Cancer; 2003 Nov; 98(9):1947-57. PubMed ID: 14584079
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium.
    Goecke T; Schulmann K; Engel C; Holinski-Feder E; Pagenstecher C; Schackert HK; Kloor M; Kunstmann E; Vogelsang H; Keller G; Dietmaier W; Mangold E; Friedrichs N; Propping P; Krüger S; Gebert J; Schmiegel W; Rueschoff J; Loeffler M; Moeslein G;
    J Clin Oncol; 2006 Sep; 24(26):4285-92. PubMed ID: 16908935
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Update of familial pancreatic cancer in Germany.
    Bartsch DK; Sina-Frey M; Ziegler A; Hahn SA; Przypadlo E; Kress R; Gerdes B; Rieder H
    Pancreatology; 2001; 1(5):510-6. PubMed ID: 12120230
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Germline Genetic Features of Young Individuals With Colorectal Cancer.
    Stoffel EM; Koeppe E; Everett J; Ulintz P; Kiel M; Osborne J; Williams L; Hanson K; Gruber SB; Rozek LS
    Gastroenterology; 2018 Mar; 154(4):897-905.e1. PubMed ID: 29146522
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Germline variation in O
    Belhadj S; Moutinho C; Mur P; Setien F; Llinàs-Arias P; Pérez-Salvia M; Pons T; Pineda M; Brunet J; Navarro M; Capellá G; Esteller M; Valle L
    Cancer Lett; 2019 Apr; 447():86-92. PubMed ID: 30677446
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Germline variation in the oxidative DNA repair genes NUDT1 and OGG1 is not associated with hereditary colorectal cancer or polyposis.
    Mur P; Jemth AS; Bevc L; Amaral N; Navarro M; Valdés-Mas R; Pons T; Aiza G; Urioste M; Valencia A; Lázaro C; Moreno V; Puente XS; Stenmark P; Warpman-Berglund U; Capellá G; Helleday T; Valle L
    Hum Mutat; 2018 Sep; 39(9):1214-1225. PubMed ID: 29900613
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.
    Walker EJ; Carnevale J; Pedley C; Blanco A; Chan S; Collisson EA; Tempero MA; Ko AH
    Fam Cancer; 2019 Apr; 18(2):241-251. PubMed ID: 30267352
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Whole-exome Sequencing Reveals New Potential Susceptibility Genes for Japanese Familial Pancreatic Cancer.
    Takai E; Nakamura H; Chiku S; Kubo E; Ohmoto A; Totoki Y; Shibata T; Higuchi R; Yamamoto M; Furuse J; Shimizu K; Takahashi H; Morizane C; Furukawa T; Yachida S
    Ann Surg; 2022 Apr; 275(4):e652-e658. PubMed ID: 32826389
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Germline mutational profile of Chinese patients under 70 years old with colorectal cancer.
    Jiang TJ; Wang F; Wang YN; Hu JJ; Ding PR; Lin JZ; Pan ZZ; Chen G; Shao JY; Xu RH; Zhao Q; Wang F
    Cancer Commun (Lond); 2020 Nov; 40(11):620-632. PubMed ID: 32914570
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer.
    Liotta L; Lange S; Maurer HC; Olive KP; Braren R; Pfarr N; Burger S; Muckenhuber A; Jesinghaus M; Steiger K; Weichert W; Friess H; Schmid R; Algül H; Jost PJ; Ramser J; Fischer C; Quante AS; Reichert M; Quante M
    JCI Insight; 2021 Mar; 6(8):. PubMed ID: 33764904
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical implications of genetic testing in familial intermediate and late-onset colorectal cancer.
    Djursby M; Hansen TVO; Wadt KAW; Madsen MB; Berchtold LA; Lautrup CK; Markholt S; Jensen UB; Krogh LN; Lundsgaard M; Gerdes AM; Nilbert M; Therkildsen C
    Hum Genet; 2022 Dec; 141(12):1925-1933. PubMed ID: 35904628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.